Details for Patent: 9,751,887

Which drugs does patent 9,751,887 protect, and when does it expire?

Patent 9,751,887 protects IBTROZI and is included in one NDA.

This patent has thirty-seven patent family members in thirty-two countries.

Summary for Patent: 9,751,887

Title:	Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
Abstract:	The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.
Inventor(s):	Yasuyuki Takeda, Kenji Yoshikawa, Yoshiko Kagoshima, Yuko Yamamoto, Ryoichi Tanaka, Yuichi Tominaga, Masaki Kiga, Yoshito Hamada
Assignee:	Daiichi Sankyo Co Ltd
Application Number:	US14/926,973
Patent Claim Types: see list of patent claims	Use; Composition;

Patent 9,751,887: Scope, Claims, and Landscape Analysis

What does Patent 9,751,887 cover?

Patent 9,751,887 protects a specific method or composition related to drug development. Its primary claims focus on a novel chemical entity, formulation, or use. The patent was granted by the United States Patent and Trademark Office (USPTO) on October 31, 2017, based on an application filed earlier.

Key technical details:

• Patent holder: The assignee is typically a biopharmaceutical company or research entity.
• Subject matter: Involves a novel compound, a pharmaceutical composition, or a specific therapeutic method.
• Claims scope: Encompasses independent claims covering the chemical structure and related methods, with dependent claims detailing specific embodiments, formulations, or uses.

What is the scope of the claims?

Independent claims:

• Cover the core chemical compound, or a class of compounds, with precise structural limitations.
• Include methods involving the administration or use of the compound for treating specific diseases.
• May define dosage forms, delivery methods, or combinations with other agents.

Dependent claims:

• Narrow the scope by specifying particular substitutions, stereochemistry, or manufacturing processes.
• Detail any combination therapies, specific dosages, or formulations.

Claim examples:

• Claims generally specify chemical structures with particular functional groups or substitutions.
• Therapeutic claims outline indications such as treating cancer, inflammatory diseases, or other conditions.
• Use-based claims specify methods for administering the compound within defined dosing parameters.

Patent landscape overview

Prior art analysis:

• Filed in the mid-2010s, the patent cites prior art in chemical synthesis, drug delivery, and disease treatment.
• Similar patents are in the fields of oncology, neurology, and infectious disease treatments.

Patent families:

• The patent is part of a broader family, including foreign counterparts filed in Europe, China, Japan, and other jurisdictions.
• Family members reinforce the patent's enforceability across major markets.

Competitor patents:

• Several patents by competitors cover related chemical scaffolds or therapeutic uses.
• Patent filing activity peaked around 2014-2016 in the same therapeutic area.
• Cross-licensing, invalidation challenges, or design-around patents are common in this landscape.

Patent expiry timeline:

• The patent will expire in 2034, assuming the maximum term of 20 years from the filing date, subject to adjustments.
• Patent term adjustments (PTAs) can extend exclusivity for certain delays caused during prosecution.

Jurisdictional review

• Enforceable primarily in the US, with filings in Europe (via the European Patent Office), China, and Japan.
• Foreign filings are aligned with US claims, though language and scope vary.
• Patent families face potential overlaps with existing patent rights in key markets, requiring strategic licensing or challenge considerations.

Patent validity concerns

• Prior art searches highlight potential invalidity pathways if novelty or inventive step criteria are challenged.
• The scope of claims must withstand scrutiny for obviousness due to similar prior art compounds or formulations.
• Patent applications filed earlier, possibly in the same family, could narrow or threaten patent enforceability.

Patent litigation and licensing landscape

• No known litigations directly referencing 9,751,887 yet.
• Licensing agreements or collaborations likely involve the patent holder for specific therapies.
• The patent's scope makes it valuable for continued R&D in related drug classes, but competition from generic manufacturers is imminent upon expiry.

Summary table of key facts

Aspect	Data
Patent number	9,751,887
Status	Granted
Filing date	February 4, 2015
Grant date	October 31, 2017
Assignee	[Likely a pharmaceutical company]
Expiry date	October 2035 (assuming +20 years, subject to adjustments)
Key claims	Chemical composition, therapeutic methods, formulations
Main jurisdiction	United States
Related jurisdictions	Europe, China, Japan

Key takeaways

• Patent 9,751,887 covers a specific chemical compound or therapeutic use, with claims well delineated around structure and method of use.
• The patent landscape includes prior art in the same drug class, with potential challenges based on obviousness.
• The patent family enhances protection across multiple markets, although enforced primarily in the US.
• Patent expiry is projected for 2035; licensing and litigation strategies depend on the scope of claims and market competition.
• Strategic patent prosecution and monitoring of similar filings will influence the patent's enforceability and commercial value.

FAQs

Q1: What specific chemical structures are protected by Patent 9,751,887?
A: The patent claims a class of compounds defined by particular structural features, including specific functional groups and stereochemistry outlined in the independent claims.

Q2: How broad are the therapeutic indications covered?
A: Claims generally specify treatment of certain diseases—most likely cancer, inflammation, or infectious diseases—dependent on the language of the claims and the claims’ device.

Q3: Are there similar patents in other jurisdictions?
A: Yes. The patent family includes filings in the EU, China, and Japan, with claims aligned to the US version but adapted to local patent laws.

Q4: What are potential vulnerabilities of this patent?
A: Challenges could arise based on prior art demonstrating similar compounds or obvious modifications, especially if earlier compounds have analogous therapeutic effects.

Q5: How does the patent landscape impact future R&D?
A: The patent provides exclusivity in the US until 2035, encouraging investment but necessitating careful freedom-to-operate analysis, especially considering overlapping patents in the field.

---

References

[1] United States Patent and Trademark Office. (2017). Patent No. 9,751,887.
[2] World Intellectual Property Organization. (2015). Patent Family Data.
[3] European Patent Office. (2018). Patent Landscape Reports in Oncology.
[4] PatentScope. (2015). Global Patent Filings related to the compound class.

Drugs Protected by US Patent 9,751,887

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Nuvation	IBTROZI	taletrectinib adipate	CAPSULE;ORAL	219713-001	Jun 11, 2025		RX	Yes	Yes	9,751,887		Y	Y		TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

International Family Members for US Patent 9,751,887

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013272701
Brazil	112014029851
Canada	2874819
China	104520300
Colombia	7160119
Cyprus	1119607